Problem

Lumius addresses the usability and cost limitations of conventional ultrasound. Most ultrasound remains 2D, forcing clinicians to move the probe while mentally reconstructing three-dimensional anatomy from thin slices. That makes procedures difficult to learn and perform consistently, particularly for less-experienced clinicians. The economic pain is substantial: existing 3D ultrasound systems cost roughly ten times more than standard 2D machines, while hospitals spend millions of dollars each year training clinicians on 2D ultrasound.

The initial and clearest use case is vascular access, especially central-line placement. Lumius says roughly 50% of first attempts fail, particularly among new clinicians, making vascular access a high-frequency procedure where better visualization could reduce failed attempts and training burden. Longer term, the company identifies blood-clot detection, nerve blocks, tumor diagnosis, and biopsy guidance as potential extensions.

Product / Service

Lumius is developing a compact, portable, hardware-based 3D ultrasound system with real-time imaging and AI assistance. Its stated goal is to provide an on-the-fly view of a volume rather than a thin 2D slice, helping users see anatomy in context and reducing the probe-coordination and interpretation burden. The system is described as affordable, with the company claiming its technology can cost 50 times less than a traditional matrix-array 3D probe, while offering a 4-by-4-by-4-centimeter field of view with near-isotropic resolution.

The underlying approach is Diffractive Acoustic Tomography, or DAT. The research behind the technology adapts an off-the-shelf linear ultrasound transducer and uses fast focal-line reconstruction to produce 3D ultrasound, with the broader research platform also supporting photoacoustic imaging. Lumius plans to add context-aware AI that can identify structures such as blood vessels, nerves, and muscle and guide the user on what is being seen and what to do next. The public materials still carry an important limitation: the products have not been evaluated by the FDA and are not intended for diagnosis or treatment.

Market

Lumius competes in medical imaging, specifically portable point-of-care ultrasound and the emerging affordable 3D ultrasound category. Its alternatives include conventional 2D ultrasound, expensive 3D systems used primarily for cardiac and fetal imaging, and adjacent handheld POCUS products from companies such as Clarius and Butterfly; GE Vscan is also cited in the handheld-ultrasound comparison landscape. These handheld vendors are relevant usability and portability comparables, although Lumius is differentiated by pursuing real-time volumetric imaging rather than only conventional handheld 2D scanning.

The company appears to be at an early commercialization stage rather than an established commercial vendor. It is listed by Y Combinator as an active Spring 2026 company, with an open hardware-and-embedded engineering role, and PitchBook reports $500,000 of funding with Y Combinator identified as an investor. The available evidence does not disclose paying customers, deployed systems, or revenue, so current traction is best characterized as launch, technical development, and initial clinical-use-case validation rather than demonstrated commercial scale.